Kedrion and ProMetic form strategic alliance to develop orphan drugs from plasma
Kedrion S.p.A. and ProMetic BioTherapeutics, Inc., a subsidiary of ProMetic Life Sciences Inc. (TSX: PLI) (“ProMetic”) have formed a strategic alliance to develop orphan drugs derived from human plasma utilizing ProMetic’s proprietary manufacturing process, the Plasma Protein Purification System (PPPS). The alliance between the two companies was created to select specific proteins which can be manufactured
Kedrion and Nabi Biopharmaceuticals announce initiation of Civacir® phase II “proof-of-concept” clinical trial
Nabi (a biopharmaceutical company based in Florida) announced today that it has initiated in the USA, further to the agreement signed with Kedrion, its Phase II “proof-of-concept” clinical trial for Civacir® [epatitis C human immune globulin]. Civacir®, when approved, would be the first therapy for the prevention of the recurrence of hepatitis C-related liver disease
“Von Willebrand Disease”: simple handbook for haemophilia centres, patients and their families
Answers to the questions most frequently asked by patients about causes, symptoms and treatments. A personal card that we recommend you to carry with you at all times. A monthly diary with annual summary. “Von Willebrand Disease – complex but not complicated (if you know about it)” is the title of the handbook which has
